International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Page 67, April 2010

Diphenylhydantoin and insulinoma

Wiwanitkit House, Bangkhae, Bangkok 10160, Thailand Tel.: +66 24132436

Received 7 October 2009; accepted 5 December 2009. published online 06 January 2010.

Article Outline

 

Editor, I read the recent publication on the use of diphenylhydantoin for treatment of insulinoma by Nabbout et al. with great interest [1]. Nabbout et al. concluded as follows: “We believe that DPH is a potent inhibitor of insulin secretion and, thus, is suitable as a temporary therapeutic measure in the preoperative period of patients with insulinoma, as well as an alternative to surgery for those who are not surgical candidates [1].” There are some sporadic reports on the success of using diphenylhydantoin [2], [3]. However, there is a need for more evidence to reach this statement. Success in a few cases might not warrant the efficacy of this new therapeutic approach for insulinoma.

Back to Article Outline

References 

  1. Nabbout LA, Salti IS, Merheb MT. Medical treatment of insulinomas: The role of diphenylhydantoin. Int J Diabetes. 2009;1:35–37
  2. Imanaka S, Matsuda S, Ito K, Matsuoka T, Okada Y. Studies on the medical treatment of non-operable insulinoma. Clinical usefulness of diphenylhydantoin-calcium antagonist. Nippon Naika Gakkai Zasshi. 1985;74(5):590–596
  3. Imanaka S, Matsuda S, Ito K, Matsuoka T, Okada Y. Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem. Jpn J Clin Oncol. 1986;16(1):65–71

PII: S1877-5934(09)00058-7

doi:10.1016/j.ijdm.2009.12.001

International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Page 67, April 2010

Article Tools